Mylan raised the EpiPen 500% and paid $465M to settle the Medicaid overcharge

Mylan acquired the EpiPen auto-injector in 2007 when it bought Merck KGaA's generics business. Over the next nine years, the company raised the price of the two-pack from roughly $100 to $609 — a 500% increase. The EpiPen was a near-monopoly product: it was the only epinephrine auto-injecter widely stocked by schools, and Mylan had aggressively marketed it to parents and institutions through programs like EpiPen4Schools, which gave free devices to schools while building brand dependence.

The pricing strategy worked for Mylan's bottom line — EpiPen generated roughly $1.5 billion in annual revenue, about 40% of the company's profit — but it came with a hidden cost. Mylan had classified EpiPen as a 'generic' drug for Medicaid rebate purposes, paying only a 13% rebate instead of the 23% brand-name rebate. The Department of Justice argued this was a deliberate misclassification, and in October 2016 Mylan agreed to pay $465 million to settle the False Claims Act allegations. The HHS Office of Inspector General estimated the government had overpaid by as much as $1.27 billion.

The public and political backlash was severe. CEO Heather Bresch was called to testify before Congress, where she could not explain the 500% price increase. The company's EpiPen4Schools program was investigated for possible antitrust violations. A Silicon Valley engineering firm disassembled an EpiPen and estimated the manufacturing cost at roughly $10 per two-pack, fueling further outrage. Bresch's mother, Senator Joe Manchin's daughter, became a political liability as the controversy exposed the family connections that had helped the EpiPen gain school access.

The settlement did not end the fallout. In 2017, Mylan's shareholders revolted over chairman Robert Coury's $98 million compensation package, which he had negotiated while the EpiPen controversy raged. The company's reputation never recovered: in 2020, Mylan merged with Pfizer's Upjohn division to form Viatris, effectively ending Mylan's independent existence. The EpiPen pricing controversy remains a standard case study in pharmaceutical pricing and corporate reputational risk.

Mylan paid $465M to settle the misclassification, which saved rebates but violated the False Claims Act, and the backlash ended its independence.

Mylan treated a life-saving monopoly product as a cash cow, raising the price 500% over nine years without improving the device — a strategy that assumed patients and schools had no alternative.

The classification of EpiPen as a 'generic' for Medicaid rebates was a deliberate distinction that saved Mylan millions in rebates but violated the False Claims Act, triggering the $465M settlement.

The CEO's family connections — her mother was a senator — became a liability when the controversy exposed how EpiPen4Schools had leveraged political access to build market dominance.

A monopoly on a life-saving drug is not a licence to raise prices 500% — the public and the government will eventually demand the cost, and the company will pay it.